Short reportsA phase II study of raltitrexed (‘Tomudex’*) in patients with hepatocellular carcinoma
Under an Elsevier user license
open archive
Keywords
chemotherapy
hepatocellular carcinoma
raltitrexed
‘Tomudex’
treatment outcome
Cited by (0)
- *
‘Tomudex’ is a trade mark, the property of Zeneca Limited.
Copyright © 1997 Kluwer Academic Publishers. Published by Elsevier Ltd. All rights reserved.